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(one from the Middle East and another
of Hispanic origin) were identified
through the PC consortium. In each
family both parents had, or were anam-
nestically inferred to have, classical PC.
Their offspring had more severe than
normal PC and the additional feature
of scalp alopecia. The phenotypic simi-
larity between these two unrelated fami-
lies from different parts of the world
strongly suggests that this represents a
genuine disease subtype. This must be
a rare occurrence in keratin diseases
given that these conditions have been
well studied for 20 years and only a
small number of epidermolysis bullosa
simplex cases with double-dominant
mutations been reported. It is important
that clinicians practicing genodermatology
be aware of these cases; experience sug-
gests that first reports are often followed
by further recognition of similar cases.
The implications for genetic counselling
are important in that affected individuals
will have a 100% chance of transmitting
the condition.
This work reminds us that even
familiar and well-studied conditions
can yield further insight into a detailed
and thoughtful clinical and genetic
study.
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Type I IFNs at the Interface between
Cutaneous Immunity and Epidermal
Remodeling
Curdin Conrad1 and Michel Gilliet1
Type I IFNs are key cytokines in antiviral host defense. Preferentially expressed by
plasmacytoid dendritic cells, type I IFNs are induced by viral infection and in
common skin wounds. In this issue, Tohyama et al. identify a new link between
type I IFNs and epidermal remodeling, by showing that type I IFNs specifically
upregulate IL-22R expression on keratinocytes and, thereby, IL-22-mediated Stat3
phosphorylation in keratinocytes. The findings suggest that type I IFNs play dual
roles in human skin: first, they induce immune activation with the induction of
IL-22-producing T cells; second, they provide the interface between immune
activation and epidermal remodeling by increasing keratinocyte responsiveness
to IL-22.
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Type I IFNs are upstream triggers of
cutaneous immunity
Type I IFNs (including IFN-a and IFN-b)
are key cytokines in antiviral host
defense, owing to their ability to limit
viral replication and to promote immune
activation (Theofilopoulos et al., 2005;
Stetson and Medzhitov, 2006). Although
produced by all nucleated cells, type I
IFNs are preferentially expressed by a
rare type of circulating cells called plas-
macytoid dendritic cells (pDCs) (Siegal
et al., 1999). pDCs produce large
amounts of type I IFNs upon TLR7- and
TLR9-mediated recognition of viral RNA
and DNA delivered into endosomal
compartments by the invading virus
(Gilliet et al., 2008). Type I IFNs are
not expressed in healthy skin, but they
are rapidly induced in virally infected
skin in association with pDC infiltration
(Wollenberg et al., 2002; Vanbervliet
et al., 2003; Gerlini et al., 2006).
Type I IFNs are also induced in
common skin wounds (Gregorio et al.,
2010). Mechanical skin injury induces
rapid infiltration of pDCs and transient
activation of TLR7 and TLR9, leading
to their short-lived expression. These
cytokines were found to initiate local
inflammatory responses and accelerate
re-epithelialization of skin wounds
(Gregorio et al., 2010). By contrast, sus-
tained type I IFN production by pDCs
was found in psoriatic skin, early in
disease formation (Nestle et al., 2005).
Here, type I IFNs were found to trigger
the activation and expansion of auto-
immune T cells, leading to epidermal
hyperplasia and the development of
psoriatic plaques (Nestle et al., 2005).
In line with these findings, excessive
IFN-a signaling in the skin of IRF2-defi-
cient mice causes an inflammatory skin
disease resembling psoriasis (Hida et al.,
2000).
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IL-22 drives epidermal remodeling
Psoriatic T cells are biased to produce the
Th17 cytokines IL-17 and IL-22 (Lowes
et al., 2007; Nestle et al., 2009). These
cytokines, especially IL-22, have key roles
in the formation and maintenance of
psoriatic plaques (Wolk et al., 2009). IL-
22 is a member of the IL-10 cytokine
family, which is secreted most notably by
Th17 cells (Liang et al., 2006); Th22 cells
produce IL-22 exclusively (Duhen et al.,
2009; Trifari et al., 2009). It is recognized
by a heterodimeric receptor consisting of
IL-22R and IL10Rb (Xie et al., 2000),
which, in the skin, is expressed exclu-
sively by keratinocytes (Wolk et al., 2004).
Binding of the cytokine to its receptor
leads to Stat3 signaling and activation of
Akt and MAPK pathways. IL-22 induces
migration and proliferation of keratino-
cytes, along with inhibiting terminal
maturation (Boniface et al., 2005; Wolk
et al., 2009). Through these mechanisms,
IL-22, which is transiently expressed upon
skin injury, may promote epidermal
remodeling with re-epithelization of skin
wounds (Eyerich et al., 2009). On the
other hand, chronic expression of IL-22
by psoriatic T cells drives keratinocyte
hyperproliferation, with the development
of epidermal hyperplasia. In line with this,
in transgenic mice, IL-22 appears to be
sufficient to induce a skin phenotype that
resembles psoriasis (Wolk et al., 2009),
and the psoriatic phenotype induced by
skin injection of IL-23, a master regulator
of Th17 development, is largely abrogated
in IL-22-deficient mice (Zheng et al.,
2007).
The link between type I IFNs and
IL-22-producing T-cell responses
The data described above suggest a link
between the early type I IFN expression in
skin and IL-22 production by T cells,
leading to epidermal remodeling of skin
wounds and keratinocyte hyperprolifera-
tion in psoriasis. But what are the mech-
anisms underlying this link? Type I IFNs
can initiate T-cell responses by inducing
differentiation and maturation of conven-
tional DCs (cDCs) (Luft et al., 1998; Santini
et al., 2000) and by directly promoting
survival and proliferation of memory
T cells (Tough et al., 1996; Marrack
et al., 1999). Type I IFNs may more speci-
fically promote IL-22 production by dif-
ferentiating monocytes into cDCs that
produce IL-23 (Santini et al., 2011), a
cytokine required for Th17 and Th22
expansion. Furthermore, type I IFNs con-
dition pDCs, to become potent drivers of
Th17 polarization (Li et al., 2011). Another
study has shown that activated pDCs are
poised to induce the differentiation of
Th22 cells although the role of type I
IFN in this process has not been
characterized (Duhen et al., 2009).
In this issue, Tohyama et al. (2012)
identify a new link between type I IFNs
and IL-22-dependent epidermal remo-
deling, by showing that type I IFNs
specifically upregulate IL-22R expres-
sion on keratinocytes and, thereby,
IL-22-mediated Stat3 phosphorylation in
keratinocytes. Thus, in skin, type I IFNs
may have dual roles: first, they induce
immune activation with the induction of
IL-22-producing T cells; second, they
provide the interface between immune
activation and epidermal remodeling by
increasing keratinocyte responsiveness
to IL-22. Another potential direct effect
of type I IFNs on keratinocytes is the
increase of MHC class I expression, which
may promote presentation of the yet-
unknown epidermal autoantigens to
T cells (Lang et al., 2005). In psoriasis,
this might lead to enhanced activation
of pathogenic autoimmune T cells pro-
ducing IL-22.
Antimicrobial peptides regulate the
expression of type I IFNs
The identification of cationic antimicro-
bial peptides (AMPs) as key regulators
of type I IFN expression in the skin has
Clinical Implications
 Type I IFNs induce immune activation of IL-22-producing T cells and
stimulate epidermal remodeling by increasing keratinocyte responsive-
ness to IL-22.
 Antimicrobial peptides regulate the expression of type I IFNs.
 New opportunities in the development of therapies for psoriasis await
further mechanistic exploration of these novel observations.
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Figure 1. Type I IFNs at the interface between cutaneous immunity and epidermal remodeling.
Skin injury (known as the Koebner phenomenon) induces transient expression of cationic antimicrobial
peptides (AMP) by keratinocytes, which form complexes with extracellular self-DNA/RNA released by
dying cells. These complexes trigger the activation of skin-infiltrating plasmacytoid dendritic cells (pDCs),
leading to type I IFN (IFN-a/b) production. Type I IFNs promote maturation of conventional DCs (cDCs),
producing IL-23 and stimulating autoreactive T cells to migrate into the epidermis. These T cells then
produce IL-17 and IL-22 upon recognition of an autoantigen presented by keratinocytes. Type I IFN also
upregulates the IL-22 receptor (IL-22R) on keratinocytes, increasing responsiveness to IL-22. IL-22 alone
induces keratinocyte hyperproliferation, leading to psoriatic epidermal hyperplasia. Together with IL-17,
IL22 also sustains production of AMPs by keratinocytes, providing a positive feedback loop that amplifies
type I IFN–driven autoimmunity.
COMMENTARY
1760 The Journal of Investigative Dermatology (2012), Volume 132
provided a breakthrough in our under-
standing of inflammatory responses in
skin wounds and psoriasis. AMPs belong
to one of the first-evolved antimicrobial
defense mechanisms of eukaryotic cells,
produced mainly by activated keratino-
cytes and neutrophils in the skin (Zasloff,
2002). The major AMPs in human skin
are the defensins, comprising multiple
cysteine-rich beta-sheet peptides, and
the cathelicidins, a family having only
one member with an alpha helical struc-
ture, called LL37. LL37 was first identi-
fied as a mediator of pDC activation
via a mechanism converting otherwise
non-stimulatory self-DNA and self-RNA
released by damaged cells into ‘‘danger
signals’’ that trigger TLR9 and TLR7 acti-
vation (Lande et al., 2007; Ganguly
et al., 2009). The mechanism involved
in this process appears to be related to
the cationic and amphiphatic structure
of LL37, which allows the formation
of complexes with negatively charged
nucleic acids, protection from extra-
cellular degradation, and transport across
cellular membranes into TLR7- and TLR9-
containing endosomal compartments of
pDCs (Ganguly et al., 2009). Other AMPs,
including inducible b-defensins, have
similar activities (Gilliet, unpublished
data), suggesting that this function is
common to several cationic AMPs. These
AMPs normally are not produced in
healthy skin, but their expression can
be rapidly and transiently induced in
injured skin (Dorschner et al., 2001;
Borkowski and Gallo, 2011). The short-
lived AMP expression parallels the
infiltration and activation of pDCs,
suggesting that this expression allows
sensing of self-nucleic acids by pDCs
(Gregorio et al., 2010). Thus, the
regulated expression of these AMPs in
injured skin may promote short-lived
type I IFN-driven inflammatory res-
ponses with transient IL-22 expression
that promotes wound re-epithelialization
of the wound.
By contrast, these AMPs are continu-
ously overexpressed in psoriasis (Frohm
et al., 1997; Ong et al., 2002), providing
an explanation for the uncontrolled
type I IFN responses that drive the deve-
lopment of T cell–mediated autoimmu-
nity. Surprisingly, Th17 cytokines IL-22
and IL-17 induce the expression of
cationic AMPs, including LL37 and
b-defensins, in keratinocytes (Wolk
et al., 2004; Liang et al., 2006; Peric
et al., 2008). IL-17 also induces chemo-
attraction of neutrophils into the skin by
triggering chemokine production by
keratinocytes (Watanabe et al., 2009).
Skin-infiltrating neutrophils in psoriasis
are also activated to release neutrophil
extracellular traps (NETs) (Lin et al.,
2011), which contain LL37–DNA com-
plexes that activate pDCs (Lande et al.,
2011). This leads to a self-sustaining
feedback loop that maintains autoim-
mune skin inflammation in psoriasis
(Figure 1). Interestingly, several genetic
variants associated with psoriasis provide
a direct genetic basis for a sustained
Th17–AMP–IFN axis in psoriasis patients.
These variants include susceptibility genes
involving the type I IFN response and
certain MHC class I molecules (involved
in autoantigen presentation to T cells)
(Sanchez et al., 2008), gene polymor-
phisms of IL-23 and IL23R (involved in
Th17 cell polarization and expansion)
(Capon et al., 2007; Cargill et al., 2007),
and gene copy number polymorphisms
of AMPs (Hollox et al., 2008).
Conclusion and future perspectives
An upstream role for type I IFN expres-
sion in epidermal remodeling of skin
wounds and psoriasis provides new
avenues for therapeutic intervention.
On one hand, TLR7/9 ligands may be
exploited to drive pDC activation and
type I IFN induction and to promote skin
re-epithelialization (e.g., chronic ulcers).
On the other hand, inhibitors of pDC
activation and type I IFN signaling
may be developed for the treatment
of psoriasis. Such therapies are being
developed and include antibodies
against IFN-a or the IFN-a/b-receptor,
antibodies against pDC-specific recep-
tors ILT7 and BDCA2, and specific
inhibitors of TLR7 and TLR9. Recently,
an anti-IFN-a antibody (MEDI-545) was
tested in a phase I clinical trial for
chronic plaque psoriasis, but it did not
achieve clinical responses (Bissonnette
et al., 2010). One possible explanation
is that MEDI-545 blocks only selective
subtypes of IFN-a while leaving other
subtypes unaffected, as suggested by the
inability of MEDI-545 to block the type I
IFN signature in skin (Bissonnette et al.,
2010). Another explanation for the
unsuccessful trial is that chronic plaque
psoriasis is not the ideal indication
for such treatment. In fact, compared
with the abundant infiltration in early
developing psoriasis lesions, pDCs are
almost absent in chronic plaque
psoriasis lesions (Albanesi et al., 2009).
At this late stage, AMP–self-nucleic acid
complexes may bypass pDC activation
and trigger direct activation of cDCs via
TLR8 (Ganguly et al., 2009). Thus, in the
chronic phase of the disease, psoriatic
inflammation may sustain itself via a
cDC–Th17–AMP loop in the absence
of pDCs and type I IFNs. However,
we believe that targeting pDC-derived
type I IFNs remains a valuable thera-
peutic strategy in acute psoriasis,
although this clinical entity remains to
be better defined. Such therapeutic
strategies may also be beneficial in
preventing relapses, an unsolved pro-
blem with current long-term therapies
for chronic psoriasis.
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